Pyxis Oncology, Inc. (PYXS) Stock

Pyxis Oncology, Inc. (PYXS) is a Healthcare stock trading at $2.03 (as of 2026-06-18), with a market capitalization of $114.04M and a trailing P/E of -1.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Pyxis Oncology, Inc. is a preclinical-stage biopharmaceutical company developing cancer therapies across immune-oncology, including investigational antibodies and immuno-therapeutics such as PYX-106 and PYX-102, and antibody-drug conjugates including PYX-201, PYX-202, and PYX-203. Its candidates target multiple solid tumors and blood cancers.

Valuation — source: SEC EDGAR (first-party)
Price	$2.03
Market Cap	$114.04M
P/E Ratio	-1.3
EV / EBITDA	-1.3
Price / Book	3.53
Price / Sales	7.88
DCF Value (model)	$-16.94
DCF Upside vs Price	-934.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$13.86M
Net Margin	-574.5%
Return on Equity	-261.4%
Current Ratio	2.76
Revenue Growth (YoY)	-14.2%
EPS Growth (YoY)	-3.0%
FCF Growth (YoY)	9.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	-7.00 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.3
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-106.4%
vs Industry	-107.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Pfizer Inc ($9.21M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Thomas Civik
Employees	44
Country	US
IPO Date	2021-10-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.